Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XFORthis companyX4 Pharmaceuticals, Inc.	$3.21	-2.14×	0.91×	4.82×	-0.43×	507.4%	82.2%	-247.4%	-225.6%	-42.5%	-32.7%	-52.4%	0.41×	2.03×	-9.79×	10.16×	0.0%	3	-1.5	2	C
ALGSAligos Therapeutics, Inc.	$4.22	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
INMBINmune Bio, Inc.	$1.15	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
KPTIKaryopharm Therapeutics Inc.	$0.04	-0.41×	-0.27×	0.55×	-1.69×	-58773.0%	95.9%	-62.1%	-134.2%	66.9%	-236.6%	-93.6%	-0.8×	-1.15×	-1.98×	1.12×	0.0%	2	-27.45	2	B-
OKUROnKure Therapeutics, Inc.	$2.86	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
SKYESkye Bioscience, Inc.	$0.95	-0.53×	1.49×	0×	-0.44×	-40.6%	0.0%	0.0%	0.0%	-279.3%	-286.6%	-144.8%	0.01×	0.1×	0×	3.3×	0.0%	1	-41.52	2	C+
Peer median	—	-0.66×	1.49×	0.55×	-0.44×	-44.6%	57.5%	-62.1%	-134.2%	-105.9%	-125.7%	-93.6%	0.01×	0.52×	0×	3.55×	0.0%	2	-16.11	2	—